| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Apoptosis Research Group and 2 Genomic Research Centre, School of Medical Science, Griffith University, Southport, Queensland, Australia; 3 Microbiology and Immunology, University of Arizona, Tucson, Arizona; 4 Veterinary Research Institute, Brno, Czech Republic; 5 ANZAC Research Institute, Concord Hospital, University of Sydney, Concord, New South Wales, Australia; and 6 Molecular Therapy Group, Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
Requests for reprints: Jiri Neuzil, Apoptosis Research Group, Heart Foundation Research Centre, School of Medical Science and the Griffith Institute of Health and Medical Research, Griffith University, Southport 9716, Queensland, Australia. Phone: 61-2-555-29109; Fax: 61-2-555-28444; E-mail: j.neuzil{at}griffith.edu.au.
"Mitocans" from the vitamin E group of selective anticancer drugs,
-tocopheryl succinate (
-TOS) and its ether analogue
-TEA, triggered apoptosis in proliferating but not arrested endothelial cells. Angiogenic endothelial cells exposed to the vitamin E analogues, unlike their arrested counterparts, readily accumulated reactive oxygen species (ROS) by interfering with the mitochondrial redox chain and activating the intrinsic apoptotic pathway. The vitamin E analogues inhibited angiogenesis in vitro as assessed using the "wound-healing" and "tube-forming" models. Endothelial cells deficient in mitochondrial DNA (mtDNA) were resistant to the vitamin E analogues, both in ROS accumulation and apoptosis induction, maintaining their angiogenic potential.
-TOS inhibited angiogenesis in a mouse cancer model, as documented by ultrasound imaging. We conclude that vitamin E analogues selectively kill angiogenic endothelial cells, suppressing tumor growth, which has intriguing clinical implications. [Cancer Res 2007;67(24):11906–13]
This article has been cited by other articles:
![]() |
P.-H. Huang, D. Wang, H.-C. Chuang, S. Wei, S. K. Kulp, and C.-S. Chen {alpha}-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis Carcinogenesis, July 1, 2009; 30(7): 1125 - 1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hahn, K. Fried, L. H. Hurley, and E. T. Akporiaye Orally active {alpha}-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer Mol. Cancer Ther., June 1, 2009; 8(6): 1570 - 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-F. Dong, R. Freeman, J. Liu, R. Zobalova, A. Marin-Hernandez, M. Stantic, J. Rohlena, K. Valis, S. Rodriguez-Enriquez, B. Butcher, et al. Suppression of Tumor Growth In vivo by the Mitocan {alpha}-tocopheryl Succinate Requires Respiratory Complex II Clin. Cancer Res., March 1, 2009; 15(5): 1593 - 1600. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |